CA2717899A1 — Stable fixed dose topical formulation
Assigned to Glenmark Pharmaceuticals Ltd · Expires 2009-09-24 · 17y expired
What this patent protects
The present invention relates to stable fixed dose topical formulations comprising an antiacne agent and an antibiotic, which exhibit storage stability at a temperature of about 40 °C and relative humidity of about 75 % for a period of at least 3 months. Particularly, the present…
USPTO Abstract
The present invention relates to stable fixed dose topical formulations comprising an antiacne agent and an antibiotic, which exhibit storage stability at a temperature of about 40 °C and relative humidity of about 75 % for a period of at least 3 months. Particularly, the present invention relates to stable fixed dose topical formulations comprising therapeutically effective amounts of (a) adapalene-containing microspheres and (b) clindamycin, a process for their preparation thereof and their use for the treatment of acne.
Drugs covered by this patent
- Benzamycin (BENZOYL PEROXIDE) · Mayne Pharma
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.